Omega-3 Fatty Acids in Patients with ASCVD Risk - The Role of Icosapent Ethyl (IPE)

Evaluate the potential clinical value of recent, large-scale clinical trials on the management of patients at high risk of having ASCVD events.

US Live Broadcast Time Zones

  • 9 AM-10 AM EDT
  • 8 AM-9 AM CDT
  • 7 AM-8 AM MDT
  • 6 AM-7 AM PDT

Europe Live Broadcast Time Zone

  • 15:00-16:00 CEST
Live Broadcast
1.00 available credits
Information
May 19, 2020
15:00 - 16:00 CEST
Online
Omega-3 Fatty Acids in Patients with ASCVD Risk - The Role of Icosapent Ethyl (IPE)
Choose a format
Details
Presenters
Related
Comments
  • Overview

    This live broadcast provides an opportunity for participants to accurately evaluate the potential clinical value of omega-3 fatty acid trials in cardiovascular disease. Amidst this progress in translational science, clinicians have several important issues to address regarding omega-3 fatty acid use so that the full benefit of the science is realized in clinical management.

    Once registered, please be on the lookout for a confirmation email with testing instructions.

  • Project Schedule

    The schedule time is in Eastern Time. Add 6 hours for (GMT + 2 for Dijon, Copenhagen).

    0900-0902

    Welcome, Introductions, Program Overview
    Børge G. Nordestgaard, MD, DMSc, Chair

    0902-0922

    Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD
    Michel Farnier, MD, PhD

    0922-0942

    Mechanisms and Comparisons of Omega-3s
    Børge G. Nordestgaard, MD, DMSc, Chair

    0942-0958

    Panel Discussion, Question & Answers
    Michel Farnier, MD, PhD
    Børge G. Nordestgaard, MD, DMSc, Chair

    0958-1000

    Closing Comments, Adjourn
    BørgeG. Nordestgaard, MD, DMSc, Chair

  • Learning Objectives

    • Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Use information on clinical utility of adjuncts to statin therapy to improve management of patients with or at high risk of ASCVD events
  • Target Audience

    This educational activity is designed for preventive/clinical cardiologists, endocrinologists, internists, general practitioners, and all other healthcare professionals, including, researchers and policy makers involved in cardiovascular preventions, primary care and rehabilitation.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Medtelligence. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1 AMA PRA CategoryCredit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • System Requirements

    For all devices:

    • Hardwired Ethernet connection is preferred, when available. Wi-Fi is also supported
    • A headset with an attached microphone is preferred for best quality audio
    • Working webcam

    Please note that the Logitech C920 and C930 models are NOT supported by Pando. 
    If you have one of these Logitech webcams, please plan to replace prior to the meeting

    Windows PC:

    Macintosh:

    • OS 10.13 or higher
    • Google Chrome or Safari
    • Mozilla Firefox also supported

    iPad:

    • iOS 11 or higher
    • Safari

Facebook Comments

Details
Presenters
Related
Comments
  • Overview

    This live broadcast provides an opportunity for participants to accurately evaluate the potential clinical value of omega-3 fatty acid trials in cardiovascular disease. Amidst this progress in translational science, clinicians have several important issues to address regarding omega-3 fatty acid use so that the full benefit of the science is realized in clinical management.

    Once registered, please be on the lookout for a confirmation email with testing instructions.

  • Project Schedule

    The schedule time is in Eastern Time. Add 6 hours for (GMT + 2 for Dijon, Copenhagen).

    0900-0902

    Welcome, Introductions, Program Overview
    Børge G. Nordestgaard, MD, DMSc, Chair

    0902-0922

    Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD
    Michel Farnier, MD, PhD

    0922-0942

    Mechanisms and Comparisons of Omega-3s
    Børge G. Nordestgaard, MD, DMSc, Chair

    0942-0958

    Panel Discussion, Question & Answers
    Michel Farnier, MD, PhD
    Børge G. Nordestgaard, MD, DMSc, Chair

    0958-1000

    Closing Comments, Adjourn
    BørgeG. Nordestgaard, MD, DMSc, Chair

  • Learning Objectives

    • Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Use information on clinical utility of adjuncts to statin therapy to improve management of patients with or at high risk of ASCVD events
  • Target Audience

    This educational activity is designed for preventive/clinical cardiologists, endocrinologists, internists, general practitioners, and all other healthcare professionals, including, researchers and policy makers involved in cardiovascular preventions, primary care and rehabilitation.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Medtelligence. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1 AMA PRA CategoryCredit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • System Requirements

    For all devices:

    • Hardwired Ethernet connection is preferred, when available. Wi-Fi is also supported
    • A headset with an attached microphone is preferred for best quality audio
    • Working webcam

    Please note that the Logitech C920 and C930 models are NOT supported by Pando. 
    If you have one of these Logitech webcams, please plan to replace prior to the meeting

    Windows PC:

    Macintosh:

    • OS 10.13 or higher
    • Google Chrome or Safari
    • Mozilla Firefox also supported

    iPad:

    • iOS 11 or higher
    • Safari

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free